Nasdaq
$3.19▼ 1.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $300.9MShares out 94.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
9- 5d agoAfter-hours26.10.20 05:064Ownership#●●●
X4 Pharmaceuticals, Inc
Insider Craig Adam R of X4 Pharmaceuticals, Inc. filed a Form 4 on October 19, 2026, reporting changes in beneficial ownership of securities as of October 16, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$3.19-1.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8After-hours26.10.09 06:238-KKey event
X4 Pharmaceuticals, Inc
X4 Pharmaceuticals has entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures. The company used a portion of the initial $80 million funding to fully repay the existing $78.7 million debt under the Hercules Loan Agreement, thereby enhancing financial flexibility. Additionally, the lenders hold the right to convert up to $15 million of the outstanding principal into common stock at a conversion price of $3.2341 per share.…more
$3.19-1.24%vs prev closeView filingShare - 10.7Regular26.10.08 00:47SCHEDULE 13G/AOwnership
X4 Pharmaceuticals, Inc
FMR LLC and its affiliates have filed a Schedule 13G/A report regarding their beneficial ownership of X4 Pharmaceuticals, Inc. The filing confirms the joint beneficial ownership status of FMR LLC and its reporting entities as of September 30, 2026.…more
$3.19-1.24%vs prev closeView filingShare
8 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Pre-market26.10.09 20:00#●●●#●●●
X4 Pharmaceuticals to Host Virtual Investor Day on October 29
X4 Pharmaceuticals will host a virtual Investor Day on October 29 to discuss the clinical status and commercial potential of mavorixafor for chronic neutropenia. Management and key opinion leaders will review the ongoing Phase 3 4WARD trial and outline future clinical development plans.…more
$3.19-1.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1After-hours26.10.02 05:30
●●●●●●●● ●●●●● ●●●●●●
X4 Pharmaceuticals has issued stock options for 80,000 shares to new employees as an employment inducement. This is a standard compensation practice under Nasdaq rules and does not represent a material change in the company's financial position.…more
$3.19-1.24%vs prev close - 9.9Pre-market26.09.09 20:00
●●●●●●●● ●●●●● ●●●●●●
X4 Pharmaceuticals announced that its management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference. This event is a standard investor relations activity and does not provide immediate material impact on the stock price.…more
$3.19-1.24%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report